Drug Discovery

The development of experimental treatments for muscular dystrophy is moving toward human trials in 2028 following encouraging results in preclinical mouse models. This milestone represents a significant leap in the application of Anthropic's Claude AI within the pharmaceutical sector, specifically

Small-scale nanoparticles are uniquely capable of penetrating the dense architecture of biofilms to disrupt the quorum sensing communication that bacteria use to maintain their survival. This revelation comes at a time when the global medical community is facing a significant crossroads, as the

Following the successful validation of its mechanism in Phase 3 trials, bitopertin is now positioned as a potential standard of care for individuals suffering from light-induced skin hypersensitivity. For many years, patients living with erythropoietic protoporphyria have navigated a world where

The clinical reality of lineage plasticity allows prostate cancer cells to survive treatment by shedding their identity and adopting forms that do not require androgen. This phenomenon presents a persistent challenge in oncology, as traditional therapies predominantly target the androgen receptor

The relentless evolution of Mycobacterium tuberculosis into multi-drug-resistant and extensively drug-resistant strains has created a critical gap that current therapeutic pipelines are unable to fill. This biological arms race has forced the scientific community to confront the limitations of

Genetic blueprints have long been visualized as sleek, predictable spirals, yet the hidden reality of our DNA involves complex architectural knots that could hold the secret to dismantling the most aggressive forms of human cancer. While the Watson-Crick double helix remains the foundation of